Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -47K | -91K | -106K | 0 | 0 |
| Operating Income | -15M | -12M | -10M | -13M | -11M |
| EBITDA | -15M | -11M | -11M | -13M | -11M |
| Net Income | -13M | -11M | -11M | -13M | -11M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.78
-0.56% today
1Y Change
-28.11%
Window
Jun 26, 2025 → Jun 24, 2026
Coverage: 250 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Microbot Medical Inc. (MBOT) is a Healthcare stock with a market cap of $100.00M and listed on NASDAQ. The stock last traded around $1.78 and down 28.1% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +60.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +60.3%, free cash flow -48.1% with operating margin 0.0% and ROIC -18.8%. Stock Foundry combines MBOT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MBOT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MBOT Max Drawdown
-64.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MBOT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$11.3M
+14.1% YoY
Free Cash Flow
-$9.4M
+19.0% YoY
Revenue Growth
+0.0%
EPS Growth
+60.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -47K | -91K | -106K | 0 | 0 |
| Operating Income | -15M | -12M | -10M | -13M | -11M |
| EBITDA | -15M | -11M | -11M | -13M | -11M |
| Net Income | -13M | -11M | -11M | -13M | -11M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 3M | 2M | 3M | 13M |
| Total Assets | 82M | 6M | 8M | 10M | 17M |
| Total Liabilities | 4M | 3M | 4M | 2M | 2M |
| Shareholder Equity | 78M | 4M | 5M | 7M | 14M |
| Total Debt | 865K | 111K | 231K | 462K | 680K |
| Net Debt | -3M | -3M | -2M | -2M | -13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+19.0% YoY
Capital Expenditures
69K
+17.9% YoY
Free Cash Flow
9M
+19.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.4%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.